Epidemiology of Prostate Cancer

Mucci, Lorelei A.; Wilson, Kathryn M.; Giovannucci, Edward

doi:10.1007/978-3-319-35153-7_9

Cited by 9 publications

(16 citation statements)

References 161 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Prostate cancer is one of the most common types of cancer among men. 48 In the past decade, the membrane-bound glycoprotein prostate-specific membrane antigen (PSMA) became an important target for both diagnosis and therapy of prostate cancer. 49 PSMA expression is relatively low in healthy prostate tissue, while it is highly expressed in prostate cancer cells.…”

Section: Radiopharmaceuticals Targeting Prostate-specific Membrane An...mentioning

confidence: 96%

Squaric Acid-Based Radiopharmaceuticals for Tumor Imaging and Therapy

et al. 2021

View full text Add to dashboard Cite

Targeting vectors bound to a chelator represent a significant fraction of radiopharmaceuticals used nowadays for diagnostic and therapeutic purposes in nuclear medicine. The use of squaramides as coupling units for chelator and targeting vector helps to circumvent the disadvantages of several common coupling methods. This review gives an overview of the use of squaric acid diesters (SADE) as linking agents. It focuses on the conjugation of cyclic chelators, e.g., DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), as well as hybrid chelators like AAZTA5 (6-pentanoic acid-6-amino-1,4-diazepine tetracetic acid) or DATA5m (6-pentanoic acid-6-amino-1,4-diazapine-triacetate) to different targeting vectors, e.g., prostate-specific membrane antigen inhibitors (KuE; PSMAi), fibroblast activation protein inhibitors (FAPi), and monoclonal antibodies (mAbs). An overview of the synthesis, radiolabeling, and in vitro and in vivo behavior of the described structures is given. The unique properties of SADE enable a fast and simple conjugation of chelators to biomolecules, peptides, and small molecules under mild conditions. Furthermore, SA-containing conjugates could not only display similar in vitro characteristics in terms of binding affinity when compared to reference compounds, but may even induce beneficial effects on the pharmacokinetic properties of these radiopharmaceuticals.

show abstract

Section: Radiopharmaceuticals Targeting Prostate-specific Membrane An...mentioning

confidence: 96%

Squaric Acid-Based Radiopharmaceuticals for Tumor Imaging and Therapy

et al. 2021

View full text Add to dashboard Cite

show abstract

Section: Prostate Cancermentioning

confidence: 99%

“…Prostate cancer is the most prevalent cancer among males, typically diagnosed in older men over 50 [72]. Diet, physical activity, and familial inheritance are responsible for the advancement of prostate cancer [72]. The majority of prostate cancers are adenocarcinomas, which contain many similarities with other cancers, e.g., breast and colon cancer [73].…”

Section: Prostate Cancermentioning

confidence: 99%

Chemotherapeutic potential of hesperetin for cancer treatment, with mechanistic insights: A comprehensive review

Sohel

Sultana

et al. 2022

Heliyon

View full text Add to dashboard Cite

Hesperetin is potential natural compound for its attributes in various anticancer activities. Hesperetin can modulate diverse signaling pathways in cancer cells related to growth, metastasis, and apoptosis. Hesperetin also increases chemosensitivity in chemotherapy in a synergistic approach. Hesperetin processes less toxicity in human body but more bioavailability, conferring its application in clinical settings.

show abstract

“…Let h 2 0 be the heritability estimate obtained from the Gaussian linear mixed model with observed binary outcomes. The expected heritability on the underlying scale h 2 1 under probit GLMM assumptions is (Fig. 1): ( ) Males diagnosed with cancer had prostate cancer, whereas females had breast cancer.…”

Section: Liability Threshold Modelmentioning

confidence: 99%

“…The lifetime risk of a woman in the United States developing breast cancer is about 13% [1]. Prostate cancer is the most common cancer among men in the US [2]. The incidence rate of prostate cancer increases with age, reaching 1 in every 52 in males between the age of 50–59 years [3, 4].…”

Section: Introductionmentioning

confidence: 99%

Family History of Breast Cancer Is Associated with Elevated Risk of Prostate Cancer: Evidence for Shared Genetic Risks

2021

View full text Add to dashboard Cite

Introduction: Although breast and prostate cancers arise in different organs and are more frequent in the opposite sex, multiple studies have reported an association between their family history. Analysis of single nucleotide polymorphism data, based on distant relatives, has revealed a small positive genetic correlation between these cancers explained by common variants. The estimate of genetic correlation based on close relatives reveals the extent to which shared genetic risks are explained by both common and rare variants. This estimate is unknown for breast and prostate cancer. Method: We estimated the relative risks, heritability, and genetic correlation of breast cancer and prostate cancer, based on the Minnesota Breast and Prostate Cancer Study, a family study of 141 families ascertained for breast cancer. Results: Heritability of breast cancer was 0.34 (95% credible interval: 0.23-0.49) and 0.65 (95% credible interval: 0.36-0.97) for prostate cancer, and the genetic correlation was 0.23. In terms of odds ratios, these values correspond to a 1.3 times higher odds of breast cancer among probands, given that the brother has prostate cancer. Conclusion: This study shows the inherent relation between prostate cancer and breast cancer; an incident of one in a family increases the risk of developing the other. The large difference between estimates of genetic correlation from distant and close relatives, if replicated, suggests that rare variants contribute to the shared genetic risk of breast and prostate cancer. However, the difference could steam from genotype-by-family effects shared between the two types of cancers.

show abstract

Epidemiology of Prostate Cancer

Cited by 9 publications

References 161 publications

Squaric Acid-Based Radiopharmaceuticals for Tumor Imaging and Therapy

Squaric Acid-Based Radiopharmaceuticals for Tumor Imaging and Therapy

Chemotherapeutic potential of hesperetin for cancer treatment, with mechanistic insights: A comprehensive review

Family History of Breast Cancer Is Associated with Elevated Risk of Prostate Cancer: Evidence for Shared Genetic Risks

Contact Info

Product

Resources

About